Cerevance Media Center

Current News

November 18, 2024

Cerevance Doses First Patient in Pivotal Phase 3 ARISE Trial of Solengepras for Treatment of Parkinson’s Disease

  • Solengepras is a potentially first-in-class, oral, non-dopaminergic investigational therapy in development for Parkinson’s disease
  • ARISE will evaluate the efficacy of solengepras as an adjunctive therapy to levodopa and other background Parkinson’s disease medications
  • Company expects to report topline data in the first half of 2026
READ FULL

November 11, 2024

Cerevance’s CVN293 Demonstrated Positive Phase 1 Results in Healthy Volunteers

  • CVN293 was generally well-tolerated in healthy volunteers for up to 14-days of continuous dosing
  • Dose-dependent exposure was observed with evidence of robust brain penetration
  • Data supports potential advancement into Phase 2 for neurodegenerative diseases characterized by neuroinflammation such as Frontotemporal Dementia, AmyotrophicLateral Sclerosis, and Alzheimer’s Disease

READ FULL

October 21, 2024

Cerevance Announces Publication of Positive Phase 2 Results of Solengepras for the Treatment of Parkinson’s Disease in eClinical Medicine

Cerevance has published the full results from the Phase 2 clinical trial of solengepras, in eClinicalMedicine, a peer-reviewed journal published by The Lancet Discovery Science Suite. The results demonstrated that solengepras, a potentially first-in-class, oral, once-daily, non-dopaminergic, GPR6 inverse agonist, significantly reduced OFF time in individuals with Parkinson’s disease and was generally well-tolerated.

READ FULL

October 17, 2024

Sarah Sheikh Joins Cerevance’s Board of Directors

Cerevance is pleased to appoint Sarah Isabel Sheikh, M.Sc., B.M. B.Ch., MRCP, to its Board of Directors, effective immediately.  Dr. Sheikh holds dual responsibilities at Takeda as the Head of Global Development for all therapeutic areas – Gastrointestinal and Inflammation, Neuroscience, Oncology, Plasma-Derived Therapies, and Vaccines – and as the Head of the Neuroscience Therapeutic Area.

READ FULL

News Archive

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No items found.

July 10, 2023

Alzheimers Association International Conference

Date:
Monday, July 17, 2023
Time:
8:45am – 4:15pm
Location:
Amsterdam, Netherlands
Media:
Presentation
Read full

June 28, 2023

XVI European Meeting on Glial Cells in Health and Disease

Date:
Monday, July 10, 2023
Time:
1:00pm – 4:00pm
Location:
Berlin, Germany
Media:
Poster
Read full

June 26, 2023

Gordon Research Conference

Date:
Sunday, July 2, 2023
Time:
Various times through July 7
Location:
Les Diablerets, VD, Switzerland
Media:
Presentation
Read full

Events Archive

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No items found.

June 27, 2024

CryoEM Structure of the human THIK-1 K2P K+ Channel Reveals a Lower ‘Y-gate’ Regulated by Lipids and Anaesthetics

Rödström, K. E.J., Eymsh, B., Proks, P., Hayre, M. S., Madry, C., Rowland, A., Newstead, S., Baukrowitz, T., Schewe, M., Tucker, S. J.

Viewview

January 26, 2023

Scalable Synthesis of CVN424, an Inverse Agonist of the GPR6 Receptor

Mu, C., Li, X., Yang, Y., Zhou, Y., Wang, C., Doyle, K.J., Ye, N., Mistry, A., Burli, R.

Viewview

December 1, 2020

First-Time Disclosure of CVN424, a Potent and Selective GPR6 Inverse Agonist for the Treatment of Parkinson’s Disease: Discovery, Pharmacological Validation, and Identification of a Clinical Candidate

Sun, H., Monenschein, H., Schiffer, H.H., Reichard, H.A., Kikuchi, S., Hopkins, M., Macklin, T.K., Hitchcock, S., Adams, M., Green, J., Brown, J., Murphy, S.T., Kaushal, N., Collia, D.R., Moore, S., Ray, W.J., English, N.M., Carlton, M.B, Brice, N.L.

Viewview

February 26, 2024

Differential Contribution of THIK‑1 K+ Channels and P2X7 Receptors to ATP‑Mediated Neuroinflammation by Human Microglia

Rifat, A., Ossola, B., Bürli, R. W. , Dawson, L. A., Brice, N. L., Rowland, A., Lizio, M., Xu, X., Page, K., Fidzinski, P., Onken, J., Holtkamp, M., Heppner, F. L., Geiger, J. R. P., Madry, C.

Viewview

March 21, 2022

The Two Pore Potassium Channel THIK-1 Regulates NLRP3 Inflammasome Activation

Drinkall, S., Lawrence, C.B., Ossola, B., Russell, S., Bender, C., Brice, N.L., Dawson, L.A., Harte, M., Brough D.

Viewview

November 21, 2022

Pharmacological Targeting of Glutamatergic Neurons within the Brainstem for Weight Reduction

Schneeberger, M., Brice, N.L., Pellegrino, K., Parolar, L., Shaked, J.T., Page, K., Marchildon, F., Barrows, D., Carroll, T.S., Tolpiko, T., Mulligan, V., Barker, D., Glen, A., Newman, R., Ortuño, M.J., Renier, N., Nectow, A.R., Cohen, P., Carlton, M., Heintz, N., Friedman, J.M.

Viewview